Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2007

View Archived Issues

Human papillomavirus vaccine 16/18 shows promise in phase III trial

Pharmacological activity of DZ-697b investigated in vitro

KDN-7438: a novel TF/FVIIa inhibitor with anticoagulant activity in vivo

Adenosine A2A agonism decreases acute inflammation and improves posthemorrhagic vasospasm in rats

Adenosine A2A antagonism has no effect on dopamine depletion-induced deficits in cognition

Epeius' targeted gene delivery system Rexin-G enters advanced phase I/II trials

Cell Genesys completes enrollment of phase III study of GVAX immunotherapy

Catalyst begins phase II trial of CPP-109 for cocaine dependence

Recent patents disclose new agents for respiratory and allergic disorders

Recent patents describe new treatment options for endocrine-related disorders

Novel therapeutic agents for obesity and lipoprotein disorders described in recent patents

J-30: a novel microtubule-disrupting agent with antitumor efficacy in vivo

Novel HDAC inhibitor described by CrystalGenomics

Fludara tablet launched in Japan

OT-551 holds promise for oncology and inflammatory conditions

Ziopharm reports positive interm data for phase II trial of ZIO-201

Critical Therapeutics begins enrollment for phase IV trial of Zyflo CR

Update on Progen's phase III trial design for liver cancer

Health Canada approves phase I trials of WBI-1001 for psoriasis

VivaGel trial begins in sexually active young women

Tercica and Genentech to codevelop Nutropin AQ and Increlex combination drug

Valeant selects pre-IND candidates for potassium-channel opener program

Inspire plans phase III trials of epinastine nasal spray for rhinitis

Peregrine advances study of bavituximab for HCV/HIV coinfection

Initial enrollment milestone reached in Vical's phase II CMV study

BioVant shows promise as adjuvant in H5N1 avian flu vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...